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INTRODUCTION
Overexpression of low molecular weight cyclin E (LMW-E), which was originally discovered in breast cancer by our group and subsequently reported by others [1] [2] [3] [4] [5] [6] [7] , is also found in ovarian cancer 8, 9 , melanoma 10 , colorectal cancer [11] [12] [13] [14] , lung cancer 15 , and renal cell carcinoma 16 . LMW-E is generated from N-terminal neutrophil elastase cleavage of the 50-KDa, full-length cyclin E1 17 . The loss of the NH2 terminus alters the subcellular localization of LMW-E to the cytoplasm, which can no longer be degraded by the nuclear FBW-7, resulting in stable and functionally active LMW-E in the cytoplasm 18 . LMW-E is not found in normal tissues, and it causes cell cycle deregulation and resistance to endocrine therapy and chemotherapy [19] [20] [21] [22] .
Compared with full-length cyclin E, LMW-E has a higher affinity for binding cyclin-dependent kinase 2 (CDK2) and is capable of phosphorylating substrates such as pRb with higher activity 23 . Transgenic mice expressing LMW-E have a higher incidence of mammary tumor development and metastasis compared with those expressing full-length cyclin E 24 , and tumorigenicity is dependent on CDK2 25 .
We previously reported an analysis of 395 patients with breast cancer in which we demonstrated that overexpression of LMW-E, as measured by Western blot analysis, is associated with distant metastases and reduced overall survival 26 . At a median follow-up of 4 years, 91.7% of patients with overexpression of cyclin E (full-length and LMW-E) according to
Western blot analysis developed distant metastases, compared with 7% of patients without cyclin E overexpression (p < 0.001). In multivariable analysis, total cyclin E expression was an independent prognostic variable and a better predictor of both disease-free and overall survival than nodal status, estrogen receptor (ER) status, or stage.
Western blot analysis is impractical for routine clinical use, which has led several groups to examine the prognostic value of cyclin E expression measured by immunohistochemistry. In these studies, cyclin E expression was scored on the basis of nuclear staining, and no consistent association between cyclin E overexpression and reduced survival was demonstrated 27 . We previously reported that LMW-E is localized predominantly in the cytoplasm, where it binds to CDK2 and has greater kinase activity than full-length cyclin E 18 . Others have reported that mislocalization of other cyclins, including cyclins A, B, and D1, has functional implications in tumorigenesis [28] [29] [30] [31] . These data suggest that examining tumors for expression of cyclins may be best assessed by immunohistochemistry to determine location (nuclear versus cytoplasmic) and intensity of staining. To test this hypothesis, we recently used separate nuclear and cytoplasmic scoring systems for both cyclin E and p-CDK2 expression to demonstrate altered cellular accumulation of these proteins using immunohistochemical analysis 32 . We evaluated 7 different cyclin E antibodies to identify the one antibody that can consistently detect cytoplasmic cyclin E in a panel of 14 breast cell lines and tumors from cyclin E transgenic mouse models and showed that nuclear versus cytoplasmic staining of cyclin E readily differentiated full-length from LMW-E, respectively. Lastly, we showed that cytoplasmic cyclin E correlated strongly with cytoplasmic p-CDK2 (P < 0.0001) in patient samples 32 .
In the present study, we tested the hypothesis that expression of LMW-E, as measured by cytoplasmic staining of cyclin E in immunohistochemistry, predicts recurrence and survival outcomes in patients with breast cancer across diverse large cohorts and subtypes.
MATERIALS AND METHODS

Patients and tissue samples
Four cohorts were analyzed in the current study (Supplementary Table 1 Figure 3 .
Western blot analysis
Fresh tissues from the 152 patients in the prospective cohort were collected and protein lysates subjected to western blot using a monoclonal antibody to the C-terminus of cyclin E (HE12, Santa Cruz Biotechnology) and actin (Roche) as previously described 26, 34 with the following modifications. Briefly, 50 µg of protein from each tumor tissue being examined was loaded into the lanes of a 10% SDS-PAGE gel and submitted to electrophoresis for 300 volt hours. These gels were then transferred to Immobilon P membrane (Millipore) by electrophoresis for 400 volt hours at 4°C. The membranes were blocked for 1 hour in BLOTTO (5% nonfat dry milk in TBST; 20 mM Tris, 137 mM NaCl, 0.25% Tween, pH 7.6). Following blocking, the membranes were incubated in primary antibodies (at a concentration of 0.1 µg/mL) in BLOTTO for 3 hours at room temperature. Following incubation with primary antibody, the membranes were washed 3 x 20 minutes in TBS-T and then incubated with goat anti-mouse or anti-rabbit IgG-horseradish peroxidase-conjugated secondary antibodies (Pierce) at a dilution of 1:3,000 in BLOTTO for 1 hour. The membrane was washed 3 x 20 minutes in TBS-T and developed with the Renaissance chemiluminescence system (Perkin-Elmer Life Sciences, Inc.). The membranes were placed in an autoradiography cassette, exposed to film, and scanned. Densitometry was performed using ImageQuant Total Lab software (Amersham Biosciences), each band quantified, and LMW-E bands were added together. Values of LMW-E and full-length cyclin E were normalized against full-length cyclin E in normal tissue.
Immunohistochemistry
Slides from all patients within each cohort were stained for cyclin E using C-terminal antibody detecting full-length cyclin E and LMW-E (rabbit polyclonal antibody to cyclin E, C-19, sc-198, Santa Cruz) as recently described 35 . Briefly, Sections (5-m-thick) of FFPE breast tumor samples were deparaffinized and rehydrated followed by incubation with 3% hydrogen peroxide and methanol to block endogenous peroxidase activity and nonspecific protein-protein interactions, respectively. Antigen retrieval was carried out with 0.01mM citric acid-based buffer at pH 6.0 using a hot plate in a metal container for 15 min before immunostaining. After 1 hour blocking for nonspecific staining, the sections were incubated with cyclin E C-19 polyclonal antibody. Antibodies were detected using a VECTASTAIN Elite ABC kit (PK6101 and PK6102; Vector Laboratories, Burlingame, CA). Cells positive for cyclin E were visualized using the chromogenic substrate 3,3'-diaminobenzidine. Slides were counterstained with hematoxylin and mounted. Tumor cell blocks known to highly express LMW-E were included in each batch and negative control were prepared by replacing the primary antibody with PBS buffer. All washing steps were performed with, first, PBS alone and then PBS with 0.1% Tween.
Cyclin E scoring was performed by three pathologists blinded to patient outcomes.
Scores (0=negative, 1=weak staining, 2=moderate staining, and 3=strong staining) were assigned for nuclear and cytoplasmic staining according to percentage of cells stained and intensity of staining (Supplemental Figure 1 ) and as described previously 32 . Each tumor sample was scored separately for nuclear and cytoplasmic cyclin E expression and LMW-E status was assigned as follows: LMW-E negative (no staining or just nuclear staining), LMW-E positive (nuclear + cytoplasmic or just cytoplasmic staining). 
Assignment of breast cancer subtype
ER, PR, and HER2 were used to approximate breast cancer subtypes. ER-and/or PRpositive and HER2-negative samples were considered hormone receptor-positive breast cancer;
HER2-positive (independent of ER and PR status) was considered HER2-positive breast cancer;
and ER-, PR-, and HER2-negative samples were considered triple-negative breast cancer (Supplementary Table 1 ).
Statistical analysis
Logistic regression was performed to determine whether full-length cyclin E and LMW-E expression as detected by Western blot analysis were associated with nuclear and cytoplasmic staining for cyclin E in immunohistochemistry. Differences in the cohorts were evaluated using chi-square tests for categorical variables and one-way analysis of variance for Ki67. Endpoints were overall survival and breast cancer freedom from recurrence (FFR) calculated from the time of diagnosis to recurrence. FFR is a modification from the recurrence-free survival endpoint from the Hudis et al guidelines 38 and was calculated as the time between the date of diagnosis and the date of first recurrence (locoregional or distant) or last follow-up (if no recurrence). FFR captures only recurrences and does not include deaths as events, regardless of cause of death.
Patients who did not experience the endpoint were censored at last follow-up.
Median follow-up times were computed using the reverse Kaplan-Meier estimator 39 .
The Kaplan-Meier method was used to calculate five-year FFR for each factor. The differences in survival curves were evaluated using log-rank test. Univariable and multivariable regression analyses were performed using Cox proportional hazards model. The final multivariable Cox models were selected using backward elimination procedure by Akaike's information criterion (AIC), which takes into account how well the model fits the data as well as the complexity of a model, thereby reducing the risk of overfitting. Model performance was quantified using concordance index (C-index) 40 , which is a measure of the probability of agreement between what the model predicts and the actual observed risk of breast cancer recurrence. The variable importance in a model is evaluated using the likelihood ratio test (LRT). Statistical analyses were performed using R version 3. 
RESULTS
Patient characteristics
There were 2,494 patients with complete data available: 303 from Lab00-222, 725 from MDA, 951 from NCI, and 515 from UK. Clinical and pathologic variables for individual cohorts and the combined cohort are summarized in Table 1 . The cohorts were distinct (P < 0.001) with respect to all variables examined except for cytoplasmic cyclin E staining. Patients in the UK cohort were older than in other cohorts (median 76 years compared with 53-62 years; P < 0.0001). Additionally, T stage, nodal status, tumor grade, and subtypes were significantly different among the cohorts (P < 0.0001). Treatment variables (chemotherapy, radiation therapy, and endocrine therapy) were also significantly distinct among cohorts (P < 0.0001). In the UK cohort, not all patients received chemotherapy. These results show that although the four cohorts were distinct in all biomarkers examined, they converged with respect to cytoplasmic cyclin E staining, suggesting that cytoplasmic cyclin E may be an independent biomarker in these patients.
Levels of full-length cyclin E and LMW-E
Tumor lysates from the 152 patients from the Lab00-222 cohort were subjected to both
Western blot analysis and immunohistochemistry with the cyclin E antibody. Nuclear and cytoplasmic staining of cyclin E were quantified and compared with results from the Western blot analysis. Tumors with undetectable or low levels of LMW-E in the Western blot analysis showed predominantly nuclear cyclin E staining, whereas tumors with high levels of LMW-E in the Western blot analysis demonstrated intense, homogeneous cytoplasmic cyclin E staining ( Figure 1A ). Logistic regression analyses were performed to determine whether LMW-E and full-length cyclin E expression in the Western blot analysis were associated with cytoplasmic and nuclear staining for cyclin E as a comprehensive score (% positive nuclei × staining intensity). Full-length cyclin E expression in Western blot analysis was an independent predictor of nuclear cyclin E staining, and LMW-E expression in Western blot analysis was an independent predictor of cytoplasmic cyclin E staining ( Figure 1A) . Thus, assessment of nuclear and cytoplasmic cyclin E staining in immunohistochemistry allowed separation into LMW-E (cytoplasmic) negative and LMW-E positive groups ( Figures 1B, Supplemental Figures 1 and 2 ).
FFR and overall survival as a function of cyclin E staining
Median follow-up for the Lab00-222 cohort was 9.8 years (95% confidence interval [CI]
9.4-10.5 years), 17.9 years (95% CI 17.4-18.6 years) for the MDA cohort, 14.8 years (95% CI 14.3-15.4 years) for the NCI cohort, and 6.3 years (95% CI 6.1-7.1 years) for the UK cohort. In the combined cohort, 981 patients (39.3%) had negative cytoplasmic cyclin E staining and 1,513
(60.7%) had positive cytoplasmic cyclin E staining, and the distributions did not differ across the four cohorts (Table 1 ).
In the univariable Cox proportional hazards model, the association between cytoplasmic cyclin E staining and FFR was significant (P < 0.01) for all four cohorts ( Table 2 ). The 5-year FFR rates for the positive cytoplasmic cyclin E staining groups compared with the negative cytoplasmic cyclin E staining groups were 86% compared with 97% for the Lab00-222 cohort, 74% compared with 93% for the MDA cohort, 69% compared with 93% for the NCI cohort, and 64% compared with 92% for the UK cohort (Supplemental Table 3 ). The hazard ratio for a patient with positive cytoplasmic cyclin E staining compared with a patient with negative cytoplasmic cyclin E staining was 4.16 for the Lab00-222 cohort, 3.19 for the MDA cohort, 4.16
for the NCI cohort, and 5.01 for the UK cohort (Table 2) .
Kaplan-Meier FFR plots for all four cohorts and all three subtype combinations as a function of cytoplasmic cyclin E staining are shown in Figure 2 . Positive cytoplasmic cyclin E staining was strongly associated with decreased FFR in all four cohorts and across all three subtype combinations, except for HER2-positive and triple-negative subtypes in the Lab00-222 cohort. The associations between cytoplasmic cyclin E staining and FFR were most striking in the hormone receptor-positive subtype.
Multivariable analysis
Clinical and treatment-related factors were represented by the following covariates: age, T stage, nodal status, tumor grade, subtype, chemotherapy, radiation therapy, and endocrine therapy. The multivariable Cox proportional hazards model was fitted in a dataset corresponding to each of the four cohorts. For these analyses, all eight clinical and treatment-related factors and cyclin E staining were initially included in the model as potential risk factors. We sequentially eliminated factors that provided decreased Akaike information criterion values to obtain the final models. The results of the multivariable analysis are displayed in Table 3 and the corresponding nomograms are displayed in Figure 3A -D.
Cytoplasmic cyclin E staining was selected in all the four cohorts, and positive cytoplasmic cyclin E staining was strongly associated with poor outcome: FFR hazard ratios were 3.19 (P = 0.012) in the Lab00-222 cohort, 2.48 (P < 0.0001) in the MDA cohort, 3.26 (P < 0.0001) in the NCI cohort, and 6.58 (P < 0.0001) in the UK cohort. In the Lab00-222 cohort, T stage, nodal status, subtype, and chemotherapy were selected along with cytoplasmic cyclin E staining, and T stage was the most significant predictor for FFR (Table 3 and Figure 3A ). In the MDA cohort, although age, T stage, nodal status, chemotherapy, and endocrine therapy were selected along with cytoplasmic cyclin E staining, the effect of cytoplasmic cyclin E staining was the strongest among these factors (Table 3 and Figure 3B ). In the NCI cohort, T stage, nodal status, tumor grade, and chemotherapy were selected along with cytoplasmic cyclin E staining;
cytoplasmic cyclin E staining had the strongest effect on FFR (Table 3 and Figure 3C ). Lastly, in the UK cohort, age, T stage, nodal status, and endocrine therapy were included in the final model; cytoplasmic cyclin E staining had the strongest effect on FFR (Table 3 and Figure 3D ). Figure 3F displays concordance indices for the final models (red) and the final models without cytoplasmic cyclin E staining for all four cohorts. The concordance indices showed substantial gains when cytoplasmic cyclin E staining was added to the model for all cohorts, especially the UK cohort, which had the largest gain.
Significance of cytoplasmic cyclin E staining from the clinical model with Ki67
Next, we sought to determine whether cyclin E had similar prognostic power using the clinical model with Ki67. Information about Ki67 was available for 692 patients in the MDA cohort. Table 4 shows the results of the final model and the corresponding nomogram is displayed in Figure 3E . The hazard ratio of positive cytoplasmic cyclin E staining compared with negative cytoplasmic cyclin E staining was 2.67 (P < 0.0001) and Ki67 was not significant at significance level 0.05 (Supplemental Table 4 ). Cytoplasmic cyclin E staining outperformed Ki67 and all other clinical factors with the highest LRT statistics with p-value <0.0001 (Supplemental Table 3 ). The nomogram shown in Figure 3E demonstrates that the prognostic power of cyclin E remained the same as in the model without Ki67 in Figure 3B for the MDA cohort.
DISCUSSION
In the current study, we examined the relationship between survival outcomes and LMW-E as measured by Western blot analysis and immunohistochemistry in patients with breast cancer. We found that LMW-E expression in Western blot analysis correlated with cytoplasmic cyclin E staining in immunohistochemistry. Cytoplasmic cyclin E staining was associated with reduced breast cancer FFR and overall survival in multivariable analysis in four different patient cohorts and across all breast cancer subtypes. In our study, patients with breast cancer whose tumors had no cytoplasmic cyclin E staining had an overall favorable prognosis, and those with any cytoplasmic cyclin E staining had a poor prognosis.
A number of investigators have examined the prognostic value of cyclin E in breast cancer. A meta-analysis of 2534 patients from 12 studies demonstrated that cyclin E overexpression was associated with a 2.32-fold increased risk of recurrence in univariate analysis and a 1.72-fold increased risk of recurrence in multivariable analysis 41 . However, an attempt to validate the association between cyclin E overexpression and poor survival in patients enrolled in the Southwest Oncology Group 9313 trial using immunohistochemistry for cyclin E on formalinfixed, paraffin-embedded tissue did not reveal significantly worse outcomes with overexpression of cyclin E 27 . We previously reported that LMW-E, not full-length cyclin E, is most active in phosphorylating substrates and that LMW-E has a higher affinity than full-length cyclin E for binding CDK 42 . LMW-E is more tumorigenic in transgenic mouse models, and patients whose tumors expressed LMW-E, as measured by Western blot analysis, were shown to be at the highest risk for recurrence and death due to breast cancer 24, 26, 43, 44 . Because LMW-E lacks the nuclear localization signal of full-length cyclin E, we previously investigated the subcellular localization of LMW-E and reported that LMW-E accumulates in the cytoplasm, where it binds to CDK2 and retains kinase activity 18 . This difference in localization could explain why studies have shown disparate results with respect to cyclin E overexpression and survival.
Key issues in the evaluation of tumor markers for clinical use are utility, magnitude, and reproducibility 45 . The clinical utility of cyclin E as a novel tumor marker is multifaceted. In terms of reproducibility, we found that cyclin E expression was stable across multiple cohorts and subtypes of breast cancer. Hence, the expression of cytoplasmic cyclin E is not dependent on the state of differentiation of the disease, but instead is related to the aggressiveness of the disease.
In terms of magnitude, cytoplasmic expression of cyclin E outperformed all other biomarkers examined in three of the four cohorts examined (MDA, NCI and UK), as shown in the stratified multivariate analysis with FFR as the endpoint (Table 3) . To provide data for the clinical relevance of cyclin E as a prognostic marker, we interrogated if cyclin E can outperform grade and Ki67 in the ER-positive breast cancer patients. We examined grade and the expression of Ki67 when available and compared to cyclin E and the results revealed that cyclin E can separate the freedom from survival plots much more significantly than Ki67. Additionally, cyclin E assessment can be readily performed in most pathology laboratories and readily interpreted by pathologists without the need for complex algorithms required for interpretation of multi-gene assays currently in use. The 21-gene recurrence score assay (Oncotype Dx, Genomic Health, Inc.) provides prognostic information for patients with early stage, estrogen receptor positive breast cancer 46 . It also provides predictive information with respect to chemotherapy benefit in patients with a high recurrence score 47 . Another multi-gene assay is the MammaPrint test (Agendia, Inc.) which measures expression of 70 genes and categorizes tumors in patients with early stage breast cancer into low risk and high risk groups 48 . This test is similar to the 21-gene recurrence score assay in that it provides both prognostic and predictive information but is applicable to both estrogen receptor positive and negative tumor types 48 . Immunohistochemistry for localization of cyclin E provides prognostic information across all subtypes in both early stage and advanced stage breast cancer. In terms of biomarker utility, cytoplasmic cyclin E can be readily detected with immunohistochemistry. The same assay will allow detection and scoring of both nuclear and cytoplasmic cyclin E using a readily available antibody and standardized scoring. The results can be interpreted without requiring complex bioinformatics and it can identify patients who may benefit from alternative treatment strategies targeting cyclin E.
LMW-E has greater affinity for CDK2 than does full-length cyclin E, and LMW-E is a target for CDK2 inhibitors. In HER-2-positive breast cancer cells expressing LMW-E, the combination of targeting HER-2 with trastuzumab and targeting LMW-E with roscovitine led to synergistic killing. 49 We propose that LMW-E not only is a prognostic marker but also could be useful as a predictive marker to identify patients who may benefit from LMW-E-targeted therapy. Previous studies of CDK inhibitors have not shown significant response rates, and therefore such inhibitors have been presumed to be ineffective. Measurement of cytoplasmic LMW-E may provide the best assessment of patients who could be treated effectively with
LMW-E-targeted therapy. In our current study, patients with all breast cancer subtypes, including triple-negative breast cancer, had reduced recurrence-free survival when cytoplasmic cyclin E staining was detected. The lack of specific targets for triple-negative breast cancer is a major challenge, and LMW-E could be a target for this aggressive disease.
The function of cytoplasmic cyclin E goes beyond cell proliferation. Historically, the function of nuclear cyclin E has been attributed to cell cycle progression, and overexpression of nuclear cyclin E leads to deregulation of cell proliferation. Cytoplasmic cyclin E, however, has alternate functions that can affect signal transduction 50 , stemness 20, 51 , and metabolism 52 , to list a few. In fact, comparing cytoplasmic cyclin E with Ki67 revealed that cyclin E was a more significant prognostic indicator than just increased cell proliferation (Supplemental Table 4 and Figure 3E and F). The non-cell cycle functions of cytoplasmic cyclin E also provide novel avenues for targeted treatment strategies for patients whose tumors express this protein. LMW-E demonstrated intense, homogeneous staining throughout the cytoplasm (e-h). Table: Tumor tissues from 318 breast cancer patients from the Lab00-222 cohort were examined for cyclin E expression by western blot analysis and immunohistochemistry. Logistic regression was performed to assess if full-length and LMW-E occurrence on Western blot predict nuclear and cytoplasmic staining for cyclin E on immunohistochemistry, respectively. Statistical analysis revealed that the presence of full-length cyclin E and the presence of LMW-E on the Western blot were independent predictors of nuclear and cytoplasmic staining, respectively. LMW, low *P values were calculated using one-way analysis of variance for Ki67 and chi-square tests for categorical variables. Table 2 . Univariable Cox regression analyses for freedom from recurrence (FFR) in the Lab00-222 (n = 303), MDA (n = 725), NCI (n = 951), UK (n = 515).
Lab00-222 MDA NCI UK HR P HR P HR P HR P Table 3 . Multivariable Cox regression analyses for freedom from recurrence (FFR) in the Lab00-222 (n = 303), MDA (n = 725), NCI (n = 951), UK (n = 515). 
